The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chebotareva A.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Dudchenko N.G.

Russian Academy for Continuing Professional Education, Moscow, Russia

The use of donepezil in gait disorders in eldery patients with dementia

Authors:

Chebotareva A.D., Dudchenko N.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2): 56‑59

DOI: 10.17116/jnevro201911909256

Read: 7859 times

Download PDF (RU)
Contact the author
Table of contents

THE USE OF DONEPEZIL IN GAIT DISORDERS IN ELDERY PATIENTS WITH DEMENTIA
THE USE OF DONEPEZIL IN GAIT DISORDERS IN ELDERY PATIENTS WITH DEMENTIA

To cite this article:

Chebotareva AD, Dudchenko NG. The use of donepezil in gait disorders in eldery patients with dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9‑2):56‑59. (In Russ.)
https://doi.org/10.17116/jnevro201911909256

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
The rela­tionship between neuropsychological indi­cators and neuroimaging changes acco­rding to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Abstract:

Donepezil is the most commonly used cholinesterase inhibitor. The indication for its use is Alzheimer’s disease. A number of clinical studies have shown its effectiveness in vascular dementia, dementia with Lewy bodies, Parkinson’s disease with dementia, dementia due to traumatic brain injury. It is shown that dementia is a risk factor for falls, and standard measures to prevent falls in the elderly are ineffective in patients with cognitive impairment. This article provides a review of publications on the influence of donepezil on gait and balance. Most authors agree that donepezil is able to improve some parameters of gait, such as gait velocity and stride time variability, which can increase stability and reduce the risk of falls. The effect of donepezil on motor function is small, but its use may be particularly valuable if other approaches to treatment of gait disorders in patients with cognitive impairment are ineffective.

Keywords:

donepezil
cholinesterase inhibitors
Alzheimer’s disease
Parkinson’s disease
walking disorders

Authors:

Chebotareva A.D.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Dudchenko N.G.

Russian Academy for Continuing Professional Education, Moscow, Russia

Close metadata

References:

  1. Brazis PW, Masdeu JC, Biller C. Localization in Clinical Neurology. Philadelphia: Lippincott Williams & Wilkins; 2001. (In Russ.)
  2. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology. 1993;43(2):268-279. https://doi.org/10.1212/wnl.43.2.268
  3. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. https://doi.org/10.1056/nejm198812293192604
  4. Sheridan PL, Hausdorff JM. The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24(2):125-137. https://doi.org/10.1159/000105126
  5. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain. 2000;123(9):1767-1783. https://doi.org/10.1093/brain/123.9.1767
  6. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001;49(5):664-672. https://doi.org/10.1046/j.1532-5415.2001.49115.x
  7. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334(7584):82. https://doi.org/10.1136/bmj.39049.706493.55
  8. Shaw FE, Bond J, Richardson DA, Dawson P, Steen IN, McKeith IG, Kenny RA. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: randomised controlled trial. BMJ. 2003;326:73. https://doi.org/10.1136/bmj.326.7380.73
  9. Shaw FE. Prevention of falls in older people with dementia. J Neural Transm. 2007;114:1259-1264. https://doi.org/10.1007/s00702-007-0741-5
  10. Rao SS. Prevention of falls in older patients. Am Fam Physician. 2005;72(1):81-88. https://doi.org/10.1080/09638280500056469
  11. Kumar A, Sharma S. Donepezil. Treasure Island (FL): Stat Pearls Publishing; 2019.
  12. Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci Ther. 2018;24(10):876-888. https://doi.org/10.1111/cns.13035
  13. Jin BR, Liu HY. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019;14(5):805-816. https://doi.org/10.4103/1673-5374.249228
  14. Hershey LA, Coleman-Jackson R. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. https://doi.org/10.1007/s40266-018-00636-7
  15. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17(3):1611-1624. https://doi.org/10.3892/etm.2018.7129
  16. Ballesteros J, Güemes I, Ibarra N, Quemada JI. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2008;23(3):171-180. https://doi.org/10.1097/01.HTR.0000319935.99837.96
  17. Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Moore R, DeKosky S. Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol. 2004;24(3):354-356. https://doi.org/10.1097/01.jcp.0000126665.88905.6a
  18. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;57(2):359-360. https://doi.org/10.1111/j.1532-5415.2009.02085.x
  19. Montero-Odasso M, Muir-Hunter SW, Oteng-Amoako A, Gopaul K, Islam A, Borrie M, Wells J, Speechley M. Donepezil improves gait performance in older adults with mild Alzheimer’s disease: a phase II clinical trial. J Alzheimers Dis. 2015;43(1):193-199. https://doi.org/10.3233/JAD-140759
  20. Montero-Odasso M, Speechley M, Chertkow H, Sarquis-Adamson Y, Wells J, Borrie M, Vanderhaeghe L, Zou GY, Fraser S, Bherer L, Muir-Hunter SW. Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. Eur J Neurol. 2019;26(4):651-659. https://doi.org/10.1111/ene.13872
  21. Kumai K, Nakamura K, Meguro K. Improved learning of sequential behaviour during cane gait training or stair climbing after femoral neck fracture: an implication for donepezil for very mild Alzheimer’s disease. Psychogeriatrics. 2017;17(2):144-145. https://doi.org/10.1111/psyg.12204
  22. Beauchet O, Launay CP, Allali G, Herrmann FR, Annweiler C. Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer’s disease. Drugs Aging. 2014;31(5):363-372. https://doi.org/10.1007/s40266-014-0175-3
  23. Beauchet O, Launay CP, Allali G, Annweiler C. Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis. CNS Drugs. 2014;28(6):513-518. https://doi.org/10.1007/s40263-014-0170-6
  24. Perez-Lloret S, Peralta MC, Barrantes FJ. Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother. 2016;17(18):2405-2415. https://doi.org/10.1080/14656566.2016.1254189
  25. Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013;73(13):1405-1415. https://doi.org/10.1007/s40265-013-0105-4
  26. Kim SD, Allen NE, Canning CG, Fung VS. Postural instability in patients with Parkinson’s disease. Epidemiology, pathophysiology and management. CNS Drugs. 2013;27(2):97-112. https://doi.org/10.1007/s40263-012-0012-3
  27. Skripkina NA, Levin OS. Gait disorders in Parkinson’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(6-2):54-60. (In Russ.) https://doi.org/10.17116/jnevro20151156254-60
  28. Lauretani F, Galuppo L, Costantino C, Ticinesi A, Ceda G, Ruffini L, Nardelli A, Maggio M. Parkinson’s disease (PD) with dementia and falls is improved by AChEI? A preliminary study report. Aging Clin Exp Res. 2016;28(3):551-555. https://doi.org/10.1007/s40520-015-0437-x
  29. Mancini M, Fling BW, Gendreau A, Lapidus J, Horak FB, Chung K, Nutt JG. Effect of augmenting cholinergic function on gait and balance. BMC Neurol. 2015;15:264. https://doi.org/10.1186/s12883-015-0523-x
  30. Yener GG, Kaya GC, Oztürk V, Akdal G. Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia. Ann Nucl Med. 2005;19(7):607-609. https://doi.org/10.1007/bf02985055
  31. Arahata H, Ohyagi Y, Matsumoto S, Furuya H, Murai H, Kuwabara Y, Nakagawa M, Yamada T, Kira J. A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil. Rinsho Shinkeigaku. 2001;41(7):402-406.
  32. Carcenac D, Martin-Hunyadi C, Kiesmann M, Demuynck-Roegel C, Alt M, Kuntzmann F. Extra-pyramidal syndrome induced by donepezil. Presse Med. 2000;29(18):992-993.
  33. Cholinesterase inhibitors: tremor and exacerbation of Parkinson’s disease. Prescrire Int. 2007;16(91):197-198.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.